[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543900":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":73,"collaborators":11,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":11,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":11,"studyType":88,"phases":89,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Hutchmed","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine","EXPERIMENTAL",null,[13],"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine",{"label":15,"type":16,"description":11,"interventionNames":17},"Nab-paclitaxel Plus Gemcitabine","ACTIVE_COMPARATOR",[18],"Drug: Nab-paclitaxel Plus Gemcitabine",{"label":20,"type":21,"description":11,"interventionNames":22},"Surufatinib with Nab-paclitaxel, and Gemcitabine","OTHER",[23],"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine",[25,29,32],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine\n\n1. Surufatinib: 200mg, qd\n2. Camrelizumab: 200mg, IV drip, Q3W, D1\n3. Nab-paclitaxel: 125 mg\u002Fm2, IV drip, D1,D8\n4. Gemcitabine : 1000 mg\u002Fm2, IV drip, D1, D8",[9],{"type":26,"name":15,"description":30,"armGroupLabels":31,"otherNames":11},"Drug: Nab-paclitaxel Plus Gemcitabine\n\n1. Nab-paclitaxel: 125 mg\u002Fm2, IV drip, D1,D8\n2. Gemcitabine : 1000 mg\u002Fm2, IV drip, D1, D8",[15],{"type":26,"name":20,"description":33,"armGroupLabels":34,"otherNames":11},"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine\n\n1. Surufatinib: 200mg, qd\n2. Nab-paclitaxel: 125 mg\u002Fm2, IV drip, D1,D8\n3. Gemcitabine : 1000 mg\u002Fm2, IV drip, D1, D8",[20],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Panfeng Tan","CONTACT","+86 21 20671828","panfengt@hutch-med.com",[42,59],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Nanjing Tianyinshan Hospital","NOT_YET_RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":51,"coordinates":52},"Point",[53,54],118.77778,32.06167,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":11,"phoneExt":11,"email":11},"Shukui Qin, Prof.",{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":48,"countryCode":49,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Tianjin Cancer Hospital","RECRUITING","Tianjin","Tianjin Municipality","300000",{"type":51,"coordinates":66},[67,68],117.17667,39.14222,{"lat":68,"lon":67},[71],{"name":72,"role":38,"phone":11,"phoneExt":11,"email":11},"Jihui Hao, Prof.",{"type":74,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100543900","phase-2-a-phase-iiiii-trial-to-evaluate-the-efficacy-and-safety-of-surufatinib-combined-with-camrelizumab-nab-paclitaxel-and-gemcitabine-in-metastatic-pancreatic-cancer-100543900",false,"NCT06361888","A Phase II\u002FIII Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","A Multicenter, Randomized, Open-label, Active-controlled, Phase II\u002FIII Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n1. Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process;\n2. Age range is 18-75 years old (inclusive);\n3. Pancreatic cancer confirmed by histology or cytology;\n4. Stage IV metastasis Pancreatic cancer patients;\n5. Have not received previous systematic first line anti-tumor treatment in the stage of metastatic pancreatic cancer;\n6. According to RECIST 1.1, there is at least one measurable lesion;\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;\n8. Expected survival time ≥ 12 weeks;\n\nExclusion Criteria:\n\n1. Use of systematic non-specific immunomodulatory therapy within 2weeks prior to the first dose；\n2. Presence of other malignancies in the past 5 years;\n3. Received major surgical surgery within 4 weeks before the first dose;\n4. Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;\n5. Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, or gemcitabine;\n6. Received strong-inducers or strong-inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose;\n7. Use of immunosuppressive drugs within 4 weeks before first dose;\n8. Known history of clinically significant liver disease, including active viral hepatitis infection or other active hepatitis or clinically significant moderate to severe cirrhosis;\n9. Patients who currently have hypertension that cannot be controlled by medication;","ALL","18 Years","75 Years",{"count":86,"type":87},502,"ESTIMATED","INTERVENTIONAL",[90,91],"PHASE2","PHASE3","To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer",[94],"Metastatic Pancreatic Cancer",[96],"First-line treatment in patients","2026-05-25",{"date":99,"type":100},"2026-05-28","ACTUAL",{"date":102,"type":100},"2024-05-08",{"date":104,"type":87},"2028-05-31",{"name":5,"class":6},2]